Drug
Dnl126
Dnl126: highest development phase Phase 1/2, developed by Denali Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL126 NCT06181136 | Phase 1/2 | Mucopolysaccharidosis Type IIIA |
Latest
No recent events.
Follow Dnl126 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.